Navigation Links
Chembio Reports 3rd Quarter 2011 Results
Date:11/3/2011

ments regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. They reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contacts:
Company Contact:
Susan Norcott 631-924-1135 x125 or
snorcott@chembio.com

Investor & Public Relations
The Investor Relations Group
212-825-3210
Adam S. Holdsworth
aholdsworth@investorrelationsgroup.com

(Tables to follow)Chembio Diagnostics, Inc.Summary of Results of Operations(Unaudited)For the three months endedFor the nine months endedSeptember 30, 2011September 30, 2010September 30, 2011September 30, 2010 Net product sales $
5,526,883$
3,786,572$
,516,325$
8,337,133 License and royalty revenue 25,00061,789125,322400,758 R&D, milestone and grant revenue 369,904656,6421,529,9722,299,970 TOTAL REVENUES $
5,921,787$
4,505,003$
3,171,619$
,037,861 GROSS MARGIN $
2,670,733$

'/>"/>

SOURCE Chembio Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results
2. Chembio Diagnostics CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News
3. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
4. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. CVS Caremark Reports Third Quarter Results
6. Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
8. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
9. Par Pharmaceutical Companies Reports Third Quarter 2011 Results
10. Luminex Corporation Reports Third Quarter 2011 Results
11. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... 7, 2011 Cempra Pharmaceuticals, a developer of ... that intravenous (IV) solithromycin demonstrates excellent ... IV doses up to 800 mg.  Oral administration ... reported Phase 1 studies.  The presentation will be ...
... May 6, 2011 Thoratec Corporation (Nasdaq: THOR ... to save, support and restore failing hearts, said today it ... 2011 Health Care Conference on Wednesday, May 11. ... will provide an update on the company, beginning at 8:40 ...
Cached Medicine Technology:Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
(Date:8/1/2015)... , ... August 01, 2015 , ... Lume Wellness creators ... is free to download on the Apple AppStore. , The app is designed ... mood, thus acting as a tool to view personal health and use this information ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers allows users to clarify, edit and delete any message including ones already sent. ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the ... the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, ... as tried-and-true products that have stood the test of time. These include lighting ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium ... day each year is the Super Bowl. In the two weeks that separate the conference ... host venue. The 2016 Super Bowl game will mark the 50th time it has been ...
Breaking Medicine News(10 mins):Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2
... ,Think About Their Drink, CHICAGO, Oct. 29 , WHO: The ... About Your Drink Family Challenge among hundreds of ... Kading family entered the photo contest by submitting a ... part of a nationwide education campaign, the ...
... Spear,s ,Toxic, Diet Causing Her Erratic Behavior?, LOS ... young Hollywood stars are imploding. Spears and others are ... fast,food. No doubt a host of issues may be ... diet of many celebrities can cause big problems. ...
... to lab tests, interpreting the clinical importance of an ... has, suggests research from the Johns Hopkins Childrens Center. ... of Pediatrics Conference Oct. 26 through Oct. 30 in ... residents, six fellows and 10 senior attending physicians in ...
... & Science University Cancer Institute researchers have found that ... their backs is a better method for delivering radiation ... to reproduce ,the positioning of the patient allowed more ... a surprising finding, according to according to Martin Fuss, ...
... in access to health care and education hinder ... cancer services and often lead to delayed cancer ... education geared toward African-Americans, researchers with the University ... The Centers for Healthy Hearts and Souls, a ...
... DHAKA, Bangladesh, Oct. 28 Therap Services will ... be held on November 6 - 8, 2007 ... World Health Organization, has set the,theme "Resources and ... as a gold sponsor. Therap Services will ...
Cached Medicine News:Health News:MilkPEP: Chicago Area Family Wins Nationwide got milk? Contest 2Health News:MilkPEP: Chicago Area Family Wins Nationwide got milk? Contest 3Health News:Bestselling Author Dr. Timothy Brantley Explains the Connection of Food and Mood 2Health News:What is a critical lab value? it depends, Hopkins researchers find 2Health News:Positioning pelvic cancer patients on stomachs for radiation yields better results 2Health News:Education program leads to lasting improvement of cancer knowledge in African Americans 2Health News:Therap Services to Attend 2nd International Conference on Intellectual Disabilities/Mental Retardation as Gold Sponsor 2
... The A5500 is an extremely accurate ... high frequency, low noise probe and fast ... application of the probe along the visual ... display, large 7 CRT monitor, built-in thermal ...
... most advanced IOL workstation. Accurate, efficient and ... be used with a variety of regressive, ... to the needs of the patient. Convenient ... a foot pedal for hands-free operation, audible ...
... unit with graphic display and IOL power ... units include firmware module with SRK II, ... All model DGH 5000e and DGH 5100e ... reducing the possibility of short readings. The ...
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w...
Medicine Products: